Pre-Made Nemvaleukin Alfa Biosimilar, Fusion Protein targeting IL2RA fused with human IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25) 139-303 (1-165): Recombinant therapeutic protein targeting CD25/IDDM10/IL2R/IMD41/TCGFR/p55 for drug discovery and mechanism of action (MOA) research

Pre-Made Nemvaleukin Alfa Biosimilar, Fusion Protein targeting IL2RA fused with human IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25) 139-303 (1-165): Recombinant therapeutic protein targeting CD25/IDDM10/IL2R/IMD41/TCGFR/p55 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Nemvaleukin alfa is an engineered cytokine that was produced by fusing circularly permuted IL-2 to the extracellular domain of the IL-2Rα subunit of the IL-2R complex. In comparison with IL-2, nemvaleukin selectively engages the intermediate-affinity IL-2R complex that is expressed on subsets of CD8+ T cells and NK cells and is sterically occluded from binding to the high-affinity IL-2R complex that is expressed preferentially on CD4+ Tregs. Nemvaleukin selectively activates and expands circulating NK cells and memory-phenotype CD8+ T cells with negligible effects on CD4+ Tregs. This selective expansion of immune effector cells with antitumor function(s) has promising therapeutic potential in patients with advanced solid tumors.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-926-1mg	1mg	3090
GMP-Bios-INN-926-10mg	10mg	Inquiry
GMP-Bios-INN-926-100mg	100mg	Inquiry
GMP-Bios-INN-926-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Nemvaleukin Alfa Biosimilar, Fusion Protein targeting IL2RA fused with human IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25) 139-303 (1-165): Recombinant therapeutic protein targeting CD25/IDDM10/IL2R/IMD41/TCGFR/p55
INN Name	Nemvaleukin Alfa
Target	IL2RA
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - IL2 (interleukin 2, IL-2) 1-59 (75-135) - IL2 (interleukin 2, IL-2) 62-132 (4-74) - human IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25) 139-303 (1-165)
VD LC	Fusion - IL2 (interleukin 2, IL-2) 1-59 (75-135) - IL2 (interleukin 2, IL-2) 62-132 (4-74) - human IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25) 139-303 (1-165)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Alkermes, Inc. (Dublin Ireland)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0